Atea Pharmaceuticals Inc

For the period ended Mar 31, 2025. Filed May 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 12, 2025

AVIR$4.41+2.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

	March 31,2025	December 31,2024
Assets
Current assets
Cash and cash equivalents	$119,394	$64,696
Marketable securities	306,042	390,025
Prepaid expenses and other current assets	8,272	7,634
Total current assets	433,708	462,355
Property and equipment, net	769	873
Other assets	4,394	197
Operating lease right-of-use assets, net	1,093	1,243
Total assets	$439,964	$464,668
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$7,387	$4,458
Accrued expenses and other current liabilities	13,549	13,345
Current portion of operating lease liabilities	811	800
Total current liabilities	21,747	18,603
Operating lease liabilities	634	842
Income taxes payable	6,499	6,356
Total liabilities	28,880	25,801
Commitments and contingencies (see Note 11)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued and outstanding	—	—
Common stock, $0.001 par value; 300,000,000 shares authorized; 85,579,475 and 84,463,059 shares issued and outstandingas of March 31, 2025 and December 31, 2024, respectively	85	84
Additional paid-in capital	809,373	802,770
Accumulated other comprehensive gain	118	233
Accumulated deficit	(398,492)	(364,220)
Total stockholders’ equity	411,084	438,867
Total liabilities and stockholders’ equity	$439,964	$464,668

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.